Shukra Pharmaceuticals (524632) Q4 24/25 earnings summary

Executive summary

• Board approved audited standalone financial results for the quarter and year ended March 31, 2025, with unmodified audit opinion from statutory auditors.

• Company operates in a single segment and reported results accordingly.

Financial highlights

• Revenue from operations for FY25 was ₹3,258.73 lakhs, down from ₹7,457.29 lakhs in FY24.

• Net profit for FY25 was ₹957.51 lakhs, a decrease from ₹1,853.72 lakhs in FY24.

• Q4 FY25 revenue was ₹1,326.98 lakhs, up from ₹1,088.39 lakhs in Q4 FY24.

• Q4 FY25 net profit was ₹538.64 lakhs, compared to ₹398.59 lakhs in Q4 FY24.

• Earnings per share (EPS) for FY25 was ₹0.22, down from ₹4.23 in FY24.

Outlook and guidance

• Auditors confirmed the company is a going concern with no material uncertainty regarding its ability to meet liabilities as they fall due.